Home » Galapagos Expands Osteoarthritis Alliance With GSK
Galapagos Expands Osteoarthritis Alliance With GSK
Galapagos NV announced that its existing multiyear alliance in osteoarthritis with GlaxoSmithKline (GSK) will be expanded.
GSK said it will bring a drug discovery program against a selected GSK target into the alliance.
Galapagos said the alliance will allow it to progress a disease-modifying drug towards completion of a Phase IIa trial, at which point GSK’s global R&D organization will be responsible for the late-stage development, production and marketing of the drug.
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May